- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- October 2025
- 160 Pages
Global
From €3525EUR$3,950USD£3,053GBP
- Report
- January 2026
- 195 Pages
Global
From €3164EUR$3,545USD£2,740GBP
€3515EUR$3,939USD£3,044GBP
- Report
- January 2026
- 198 Pages
Global
From €3164EUR$3,545USD£2,740GBP
€3515EUR$3,939USD£3,044GBP
- Report
- January 2026
- 195 Pages
Global
From €3164EUR$3,545USD£2,740GBP
€3515EUR$3,939USD£3,044GBP
- Report
- August 2025
- 193 Pages
Global
From €3164EUR$3,545USD£2,740GBP
€3515EUR$3,939USD£3,044GBP
- Report
- January 2026
- 180 Pages
Global
From €3164EUR$3,545USD£2,740GBP
€3515EUR$3,939USD£3,044GBP
- Report
- August 2025
- 192 Pages
Global
From €3164EUR$3,545USD£2,740GBP
€3515EUR$3,939USD£3,044GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,470GBP
- Report
- August 2025
- 185 Pages
Global
From €4016EUR$4,500USD£3,478GBP
- Clinical Trials
- July 2025
- 80 Pages
Global
From €1785EUR$2,000USD£1,546GBP
- Drug Pipelines
- April 2025
- 180 Pages
Global
From €2231EUR$2,500USD£1,932GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1115EUR$1,250USD£966GBP
- Report
- June 2025
- 150 Pages
Global
From €2409EUR$2,699USD£2,086GBP
- Report
- December 2025
- 150 Pages
Global
From €4328EUR$4,850USD£3,748GBP

Tacrolimus is an immunosuppressant drug used to treat immune disorders such as rheumatoid arthritis, psoriasis, and Crohn's disease. It works by inhibiting the production of certain proteins that are involved in the body's immune response. Tacrolimus is typically administered orally or intravenously, and is available in both generic and branded forms. It is also used to prevent organ rejection in transplant patients.
Tacrolimus is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other drugs. It is generally well tolerated, with few side effects. However, it can cause serious side effects, such as an increased risk of infection and an increased risk of developing certain types of cancer.
The tacrolimus market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, and Sanofi. Other companies include Mylan, Teva, and Sun Pharmaceuticals. Show Less Read more